<DOC>
	<DOCNO>NCT00453570</DOCNO>
	<brief_summary>As per request Heath Authorities , present clinical study assess immunogenicity safety sanofi pasteur 's DTacP-IPV// PRP~T combine vaccine ( PENTAXIM™ ) three-dose primary vaccination 2 , 3 , 4 month age 3 , 4 5 month age follow booster dose 18-20 month age compare commercially available DTacP , Hib conjugate ( Act-HIB™ ) IPV ( IMOVAX Polio™ ) monovalent vaccine order meet requirement registration product People 's Republic China .</brief_summary>
	<brief_title>Immunogenicity Safety Pentaxim 3 Doses Primary Vaccination Followed Booster Dose 18 Months</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 month ( 60 74 day ) inclusive day inclusion Born full term pregnancy ( ³36 week ) birth weight ≥ 2.5 kg Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure Exclusion Criteria : Participation another clinical trial 4 week precede trial inclusion Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component history life threaten reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive past Any vaccination perform planned 4 week precede first trial visit ( except BCG Hepatitis B , give within 8 day first study visit ) Vaccination plan 4 week follow trial vaccination ( except BCG Hepatitis B , give within 8 day study vaccine ( ) administration ) History diphtheria , tetanus , pertussis , poliomyelitis , Haemophilus influenzae type b infection ( confirm either clinically , serologically microbiologically ) Clinical serological evidence systemic illness include Hepatitis B , Hepatitis C and/or HIV infection Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis disease Haemophilus influenzae type b infection trial vaccine another vaccine Thrombocytopenia bleeding disorder contraindicate intramuscular vaccination History of/current seizure Febrile illness ( axillary temperature ≥ 37.1°C ) acute illness day inclusion</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>74 Days</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diphteria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Pertussis</keyword>
</DOC>